Dimopoulos MA, et al. - Researchers undertook the randomized phase 3 ELOQUENT-2 study (NCT01239797) to determine the effectiveness and safety of elotuzumab plus lenalidomide and dexamethasone (ELd) vs lenalidomide and dexamethasone (Ld) in relapsed/refractory multiple myeloma (RRMM). This study included the longest follow-up (4 years) to date of any monoclonal antibody in patients with RRMM. Outcomes revealed that the progression-free survival benefit and long-term safety of ELd seen at 2 and 3 years was maintained at 4 years. This supports the premise that, for the long-term treatment of patients with RRMM, ELd is a valuable therapeutic option.